Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

Inclusion Criteria:

• mPAP ≥ 21mmHg, PAWP ≤ 25mmHg, and PVR ≥3 WU
• Classified as WHO group I-III pulmonary hypertension

Exclusion Criteria:

• WHO group IV and V pulmonary hypertension
• Patients who are on baseline pulmonary vasodilator medications
• Severe aortic or mitral valve disease
• Patients who are pregnant
• Left ventricular ejection fraction of <35%
• Patients who are hospitalized as inpatients at the time of RHC
• Patients with systolic blood pressure <90mmHg or mean arterial pressure of < 60mmHg